共有 50 笔近期内部人交易记录记录，涉及 Xilio Therapeutics, Inc. (XLO), 包括 36 笔买入 和 11 笔卖出. 内部人买入总额为 $14.86M 内部人卖出总额为 $12.1M.
近期活跃的重要内部人包括 Shannon James Samuel, Gilead Sciences, Inc., Brennan Kevin M.. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.
内部人交易记录 — XLO
| 日期 |
姓名 |
职位 |
交易类型 |
股数 |
平均价格 |
总价值 |
持股数量 |
| 2026-03-26 |
Shannon James Samuel |
Director |
知情买入 |
5,000 |
$8.79 |
$43.95K |
10,000 |
| 2026-02-13 |
Gilead Sciences, Inc. |
10 Percent Owner |
知情买入 |
3,739,000 |
$0.00 |
$373.90 |
40,384,266 |
| 2026-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
知情卖出 |
1,826 |
$0.64 |
$1.17K |
6,371 |
| 2026-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
知情卖出 |
7,030 |
$0.64 |
$4.52K |
24,766 |
| 2026-01-01 |
Russo Rene |
President and CEO |
期权行权（卖出） |
44,250 |
- |
- |
88,500 |
| 2026-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
期权行权 |
5,000 |
- |
- |
8,197 |
| 2026-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
期权行权 |
19,375 |
- |
- |
31,796 |
| 2026-01-01 |
Luptakova Katarina |
Chief Medical Officer |
期权行权 |
16,625 |
- |
- |
33,250 |
| 2025-12-31 |
Russo Rene |
President and CEO |
限制性股票授予 (RSU) |
1,500,258 |
$0.84 |
$1.26M |
1,500,258 |
| 2025-12-31 |
Brennan Kevin M. |
SVP, Finance and Accounting |
限制性股票授予 (RSU) |
95,221 |
$0.84 |
$80.08K |
95,221 |
| 2025-12-31 |
Frankenfield Christopher James |
Chief Financial Officer |
限制性股票授予 (RSU) |
668,789 |
$0.84 |
$562.45K |
668,789 |
| 2025-12-31 |
Luptakova Katarina |
Chief Medical Officer |
限制性股票授予 (RSU) |
451,885 |
$0.84 |
$380.04K |
451,885 |
| 2025-11-26 |
Gilead Sciences, Inc. |
10 Percent Owner |
实值期权行权 |
13,335,000 |
$0.75 |
$10M |
- |
| 2025-11-21 |
Russo Rene |
President and CEO |
股份退回 |
135,134 |
$11.69 |
$1.58M |
- |
| 2025-11-21 |
Brennan Kevin M. |
SVP, Finance and Accounting |
股份退回 |
20,000 |
$1.08 |
$21.6K |
- |
| 2025-11-21 |
Frankenfield Christopher James |
Chief Financial Officer |
股份退回 |
150,000 |
$2.75 |
$412.5K |
- |
| 2025-11-21 |
Luptakova Katarina |
Chief Medical Officer |
股份退回 |
25,000 |
$2.79 |
$69.63K |
- |
| 2025-06-17 |
Shannon James Samuel |
Director |
知情买入 |
25,000 |
$0.69 |
$17.22K |
70,000 |
| 2025-06-16 |
Shannon James Samuel |
Director |
知情买入 |
45,000 |
$0.69 |
$30.87K |
45,000 |
| 2025-06-16 |
Russo Rene |
President and CEO |
知情买入 |
36,289 |
$0.68 |
$24.68K |
281,172 |
| 2025-06-11 |
Clancy Paul J |
Director |
限制性股票授予 (RSU) |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Shannon James Samuel |
Director |
限制性股票授予 (RSU) |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Bonstein Sara |
Director |
限制性股票授予 (RSU) |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Brennan Aoife |
Director |
限制性股票授予 (RSU) |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Ross Robert W. |
Director |
限制性股票授予 (RSU) |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Rossi Christina |
Director |
限制性股票授予 (RSU) |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Xu Yuan |
Director |
限制性股票授予 (RSU) |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Curran Daniel J. |
Director |
限制性股票授予 (RSU) |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Officer |
未知 |
- |
- |
- |
- |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Director |
限制性股票授予 (RSU) |
62,000 |
$0.70 |
$43.4K |
62,000 |
| 2025-06-05 |
Gilead Sciences, Inc. |
10 Percent Owner |
知情买入 |
13,335,000 |
$0.75 |
$10M |
13,335,000 |
| 2025-04-15 |
Russo Rene |
President and CEO |
限制性股票授予 (RSU) |
190,000 |
$0.71 |
$135.28K |
190,000 |
| 2025-04-15 |
Frankenfield Christopher James |
Chief Financial Officer |
限制性股票授予 (RSU) |
75,000 |
$0.71 |
$53.4K |
75,000 |
| 2025-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
知情卖出 |
1,803 |
$0.98 |
$1.77K |
3,197 |
| 2025-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
知情卖出 |
6,954 |
$0.98 |
$6.84K |
12,421 |
| 2025-01-01 |
Russo Rene |
President and CEO |
期权行权（卖出） |
44,250 |
- |
- |
132,750 |
| 2025-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
期权行权 |
5,000 |
- |
- |
5,000 |
| 2025-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
期权行权 |
19,375 |
- |
- |
19,375 |
| 2025-01-01 |
Luptakova Katarina |
Chief Medical Officer |
期权行权 |
16,625 |
- |
- |
16,625 |
| 2025-01-01 |
Russo Rene |
Officer |
未知 |
- |
- |
- |
- |
| 2024-12-18 |
Gilead Sciences, Inc. |
10 Percent Owner |
知情买入 |
1,759,978 |
$1.04 |
$1.83M |
9,105,451 |
| 2024-10-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
限制性股票授予 (RSU) |
26,000 |
$0.75 |
$19.5K |
26,000 |
| 2024-08-03 |
Frankenfield Christopher James |
Chief Operating Officer |
限制性股票授予 (RSU) |
52,000 |
$0.90 |
$46.54K |
52,000 |
| 2024-06-14 |
Clancy Paul J |
Director |
限制性股票授予 (RSU) |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Bonstein Sara |
Director |
限制性股票授予 (RSU) |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Ross Robert W. |
Director |
限制性股票授予 (RSU) |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Rossi Christina |
Director |
限制性股票授予 (RSU) |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Xu Yuan |
Director |
限制性股票授予 (RSU) |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Curran Daniel J. |
Director |
限制性股票授予 (RSU) |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-13 |
Shannon James Samuel |
Officer |
未知 |
- |
- |
- |
- |
■ 知情交易 — 公开市场买卖（最具参考价值）
■ 非知情买入 — 奖励、期权行权、转换
■ 非知情卖出 — 税务代扣、归属出售
■ 中性 — 礼赠、信托、到期
